CMMB
Chemomab Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.23
+4.24%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.24
From 52W high−56.54%
Volume28457.00
Market cap$9.01M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.24
From 52W high
−56.54%
Volume
28457.00
Market cap
$9.01M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
36.9
MomentumView details →
1D Return
+4.24%
YTD Return
−29.70%
SummaryUpdated Jun 1, 2026
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) is a clinical-stage biotechnology company founded in 2011 and headquartered in Tel Aviv, Israel. The company went public in February 2019 and was formerly known as Anchiano Therapeutics Ltd. before changing its name to Chemomab Therapeutics in March 2021. Chemomab focuses on developing innovative therapeutics for the treatment of inflammation and fibrosis, conditions that affect millions of patients worldwide and represent significant unmet medical needs.
Similar companies
Latest newsMore news →
The U.S. Securities and Exchange Commission declared effective the Form S-4 registration statement filed by Chemomab Therapeutics Ltd. and Snowdrift Parent Corp for the proposed business combination with Scipher Medicine.2d agoChemomab Therapeutics announced that its planned merger with Scipher Medicine is advancing, with closing expected by year-end.77d ago